Georgia Research Alliance

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.

EarliTec Diagnostics is a digital health company focused on the early identification and treatment of autism spectrum disorder (ASD) and related disabilities in children. The company was developed by prominent researchers from Children’s Healthcare of Atlanta, Emory University School of Medicine, and Yale University. EarliTec is at the forefront of creating biomarkers that provide insights into how children perceive their environment. Its innovative technology utilizes dynamic quantification of social-visual engagement (DQSVE) to monitor looking behavior that is often undetectable to the naked eye. This capability enables parents, providers, and caregivers to implement personalized and timely therapeutic interventions for children.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

TendoNova is a medical technology company focused on developing systems for office-based orthopedic procedures that address tendon injuries and pain. The company specializes in creating micro-invasive devices that facilitate percutaneous tenotomy, which can be performed under ultrasound guidance. This approach allows physicians to deliver tailored treatment options that meet the specific needs of individual patients while minimizing additional costs. By providing customizable modalities, TendoNova enhances the capabilities of clinicians, promoting effective and efficient orthopedic care in an office setting.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Aviabiotic creates probiotics for integrated poultry companies. The probiotic, genetically engineered for thermostability, elimination of antibiotic resistance, and dependence on corn sugar (to protect the environment from recombinant DNA after it has left the chicken), will produce eicosapentanoic acid, a heart-healthy, Omega-3 fatty acid. Genetically engineered Bacillus subtilisspores in the chicken’s small intestine convert conventional poultry feed into helpful Omega-3 fatty acids. While currently in the concept stage, Aviabiotic has the tools to create a functional prototype for further testing purposes.

Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse model in the next phase of development. This technique, the passive administration of antibodies, importantly does not require a functioning immune response, making this ideally suited to immunocompromised patients needing protection from this bacterial pathogen.

AngioCloud is a developer of cloud-based 3D imaging software that facilitates the sharing and analysis of high-quality vascular images. This software enables medical professionals to access and collaborate on 3D vascular cases from any connected device, whether desktop or mobile. By providing unprecedented ease of access to critical imaging, AngioCloud enhances various aspects of medical practice, including diagnosis, pre-surgical planning, and the selection of medical devices. The platform supports e-consults and clinical decision-making, ultimately streamlining surgical processes and improving patient outcomes.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.

BioData Consortium builds a third-party platform to aggregate and distribute anonymized, high quality-clinical data. This professionally curated data can be used to train artificial intelligence and deep learning technology, improving outcomes and driving down costs in radiology. Developed by radiologists and data professionals, BDC aims to be the largest repository of the highest-quality data available to medical technology researchers. The company is experienced in following HIPAA guidelines and working with federally regulated confidential data. BioData Consortium clients include leading research hospitals and healthcare provider networks.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

PNP Therapeutics, Inc. is a biopharmaceutical company based in Birmingham, Alabama, focused on developing innovative treatments for cancer. Established in 2000, the company utilizes a platform technology centered around a patented enzyme derived from E. coli purine nucleoside phosphorylase. This enzyme works with various nucleoside prodrugs to produce active metabolites that exhibit significant anti-tumor activity. PNP Therapeutics aims to enhance cancer treatment by providing nucleoside prodrugs that directly target and destroy tumor cells, thereby improving the overall effectiveness of cancer therapies for patients.

TendoNova is a medical technology company focused on developing systems for office-based orthopedic procedures that address tendon injuries and pain. The company specializes in creating micro-invasive devices that facilitate percutaneous tenotomy, which can be performed under ultrasound guidance. This approach allows physicians to deliver tailored treatment options that meet the specific needs of individual patients while minimizing additional costs. By providing customizable modalities, TendoNova enhances the capabilities of clinicians, promoting effective and efficient orthopedic care in an office setting.

HAWA Therapeutics creates a novel treatment for muscle strain, damage, and dystrophy stimulating muscle stem cell functions. The treatment involves injecting HIF2ai inhibitors into the muscle, but the company is also exploring topical and oral approaches. Moderate and severe muscle strains can cause immense pain, causing people to be out of work for long periods of time. Treatment options are limited to physical therapy, surgery, and a host of short-term drugs such as anti-inflammatories. Severe strains often heal incompletely, making people susceptible to further injury. HAWA’s HIF2Ai technology accelerates initial recovery and reduces recurrent injuries by preventing the formation of scar tissue.

Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists. The drugs Pyrefin is testing have myriad potential uses, including treatment for epileptic seizures. Rodent trials have shown efficacy in treatment for seizure-induced brain injury, endometriosis, and osteoarthritis without behavioral or organ toxicity after 30 days. Phase 1A of GRA’s venture development support focused Pyrefin’s team on prioritizing the clinical use of its treatment.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

Kodikaz Therapeutic Solutions is focused on advancing cancer treatment by developing targeted therapies aimed at eradicating cancers while minimizing side effects. The company utilizes its innovative Zip-Code™ Technology platform, a first-in-class delivery system that facilitates cell-specific genomic transfer for both RNA and DNA applications. Rooted in discoveries from human cancers, this platform addresses the limitations associated with traditional viral delivery methods, providing a more effective and safer alternative. Kodikaz's research generates valuable in-vitro and in-vivo data across various oncological applications, including pancreatic, myeloma, and colorectal cancers, supporting the development of curative gene transfer technologies.

BioData Consortium builds a third-party platform to aggregate and distribute anonymized, high quality-clinical data. This professionally curated data can be used to train artificial intelligence and deep learning technology, improving outcomes and driving down costs in radiology. Developed by radiologists and data professionals, BDC aims to be the largest repository of the highest-quality data available to medical technology researchers. The company is experienced in following HIPAA guidelines and working with federally regulated confidential data. BioData Consortium clients include leading research hospitals and healthcare provider networks.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.

Abby Med operates a pharmaceutical company that specializes in developing drugs for treating cancer.

TendoNova is a medical technology company focused on developing systems for office-based orthopedic procedures that address tendon injuries and pain. The company specializes in creating micro-invasive devices that facilitate percutaneous tenotomy, which can be performed under ultrasound guidance. This approach allows physicians to deliver tailored treatment options that meet the specific needs of individual patients while minimizing additional costs. By providing customizable modalities, TendoNova enhances the capabilities of clinicians, promoting effective and efficient orthopedic care in an office setting.

Pyrefin is a development-stage pharmaceutical company focused on producing EP2 receptor antagonists. The drugs Pyrefin is testing have myriad potential uses, including treatment for epileptic seizures. Rodent trials have shown efficacy in treatment for seizure-induced brain injury, endometriosis, and osteoarthritis without behavioral or organ toxicity after 30 days. Phase 1A of GRA’s venture development support focused Pyrefin’s team on prioritizing the clinical use of its treatment.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

Cognition Medical Corp. is a medical device company based in Cambridge, Massachusetts, focused on developing innovative therapy solutions for acute stroke patients. Incorporated in 2012, the company specializes in devices that remove blood clots from the brain through minimally invasive techniques, eliminating the need for surgery. Their technology allows for navigation through catheters within blood vessels to safely retrieve clots while also protecting the brain from potential over-oxygenation that can occur after blocked vessels are reopened. Cognition Medical aims to improve the safety and efficiency of stroke procedures, ultimately reducing brain damage and promoting healthier outcomes for patients. The company combines expertise across various fields, including engineering, biology, and interventional medicine, to advance its mission.

Aviabiotic creates probiotics for integrated poultry companies. The probiotic, genetically engineered for thermostability, elimination of antibiotic resistance, and dependence on corn sugar (to protect the environment from recombinant DNA after it has left the chicken), will produce eicosapentanoic acid, a heart-healthy, Omega-3 fatty acid. Genetically engineered Bacillus subtilisspores in the chicken’s small intestine convert conventional poultry feed into helpful Omega-3 fatty acids. While currently in the concept stage, Aviabiotic has the tools to create a functional prototype for further testing purposes.

Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called “stroma,” which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. Early testing of the company’s targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

Diasyst specializes in developing innovative solutions for chronic disease management, focusing primarily on diabetes. The company offers a Medication Intelligence platform that empowers healthcare providers to make informed treatment decisions efficiently. By gathering and analyzing critical real-time data through proprietary algorithms, Diasyst provides tailored medication intervention recommendations, enhancing the ability of care teams to deliver safe and effective treatment. Their extensive knowledge base, built from decades of research at Emory University and the VA, encompasses clinical guidelines, drug labels, and best practices. This approach not only aims to improve patient care and engagement but also seeks to optimize clinical and financial outcomes by reducing the risks of complications associated with chronic conditions.

Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse model in the next phase of development. This technique, the passive administration of antibodies, importantly does not require a functioning immune response, making this ideally suited to immunocompromised patients needing protection from this bacterial pathogen.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

Centizyme develops a nanoparticle-based treatment for severe asthma. The therapy, called GeneRegs, is made from gold nanoparticles, coated with an enzyme that directly targets a protein that causes asthma symptoms. Because the gold nanoparticles are so small, they can be safely inhaled, delivering targeted therapy directly to the lungs – unlike oral steroids, which attack that same protein throughout the entire body. The systemic approach of steroids suppresses the immune system and causes other negative side effects, including osteoporosis and diabetes. The targeted approach of GeneRegs makes it a promising therapy that could provide a better and safer alternative to oral steroids and improve outcomes for approximately 1.5 million patients with severe asthma.

BioPace develops a hardware-free “biological pacemaker” to complement or replace traditional implantable devices. The technology uses mRNA-mediated gene transfer – called Tbx18 transduction – to deliver a human gene that dictates the formation of pacemaker tissue. When TBX18 is re-expressed within an adult human, the hallmark features of native pacemaker tissue in the heart are reproduced. When combined with a small molecule, A83-01, TBX18-induced pacemaker cells have proven durable. BioPace’s published data demonstrates the feasibility of the concept in small and large animal models. As of spring 2021, the company was working to further validate the concept for clinical application.

PNP Therapeutics, Inc. is a biopharmaceutical company based in Birmingham, Alabama, focused on developing innovative treatments for cancer. Established in 2000, the company utilizes a platform technology centered around a patented enzyme derived from E. coli purine nucleoside phosphorylase. This enzyme works with various nucleoside prodrugs to produce active metabolites that exhibit significant anti-tumor activity. PNP Therapeutics aims to enhance cancer treatment by providing nucleoside prodrugs that directly target and destroy tumor cells, thereby improving the overall effectiveness of cancer therapies for patients.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

PDx Scan develops a way to assess the degeneration that comes from Parkinson’s disease using a magnetic resonance imaging (MRI) scan. The approach offers significant advantages over the only existing neuro-imaging technique approved by the FDA for diagnosing Parkinson’s. The current technique is quite costly, and the images it creates aren’t detailed enough to assess how well a Parkinson’s treatment being tested in clinical trials is working. PDx Scan designed a machine-learning algorithm to work hand-in-hand with a multi-contrast MRI scan. It would be more affordable than the current technique, and it would provide more useful information to researchers in clinical trials. Initially, the startup is making this technology available to hospitals and healthcare systems to aid in various clinical diagnoses and plans of care. PDx Scan is aiming to expand to clinical trials for Parkinson’s treatment, where the technology can be used to select participants in the trial and assess their progress.

BioPace develops a hardware-free “biological pacemaker” to complement or replace traditional implantable devices. The technology uses mRNA-mediated gene transfer – called Tbx18 transduction – to deliver a human gene that dictates the formation of pacemaker tissue. When TBX18 is re-expressed within an adult human, the hallmark features of native pacemaker tissue in the heart are reproduced. When combined with a small molecule, A83-01, TBX18-induced pacemaker cells have proven durable. BioPace’s published data demonstrates the feasibility of the concept in small and large animal models. As of spring 2021, the company was working to further validate the concept for clinical application.

RePredix develops an acuity algorithm to predict and warn patients of potential heart failure. Its initial algorithm proved that heart failure can be diagnosed using wristband data.

Migra Therapeutics is developing nanotechnology therapies for cancer. Some types of cancer, particularly pancreatic cancer and breast cancer, are comprised of dense barrier cells called “stroma,” which resist penetration by drug therapy. Migra Therapeutics has engineered a protein that targets a receptor in these cancer cells; the protein binds to the cancer cells to deliver therapies more effectively. Migra’s system can be used to deliver chemotherapy drugs, therapeutic antibodies and most importantly, nanoparticle drugs. Early testing of the company’s targeted drug delivery system has shown promising results for treating pancreatic and breast cancer. More testing is needed, but the company aims to fundamentally change the future of nanotechnology cancer treatment.

Covanos is a development-stage medical technology company focused on diagnosing and treating cardiac and vascular diseases. The company specializes in creating advanced digital medical diagnostic software solutions that leverage sophisticated mathematical methods and computational fluid dynamics. Their software evaluates coronary obstructions by analyzing CT angiography images of the heart, providing critical clinical information to physicians in near real-time. This enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance medical diagnostics in the cardiovascular field, ultimately improving patient outcomes.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Cognition Medical Corp. is a medical device company based in Cambridge, Massachusetts, focused on developing innovative therapy solutions for acute stroke patients. Incorporated in 2012, the company specializes in devices that remove blood clots from the brain through minimally invasive techniques, eliminating the need for surgery. Their technology allows for navigation through catheters within blood vessels to safely retrieve clots while also protecting the brain from potential over-oxygenation that can occur after blocked vessels are reopened. Cognition Medical aims to improve the safety and efficiency of stroke procedures, ultimately reducing brain damage and promoting healthier outcomes for patients. The company combines expertise across various fields, including engineering, biology, and interventional medicine, to advance its mission.

Centizyme develops a nanoparticle-based treatment for severe asthma. The therapy, called GeneRegs, is made from gold nanoparticles, coated with an enzyme that directly targets a protein that causes asthma symptoms. Because the gold nanoparticles are so small, they can be safely inhaled, delivering targeted therapy directly to the lungs – unlike oral steroids, which attack that same protein throughout the entire body. The systemic approach of steroids suppresses the immune system and causes other negative side effects, including osteoporosis and diabetes. The targeted approach of GeneRegs makes it a promising therapy that could provide a better and safer alternative to oral steroids and improve outcomes for approximately 1.5 million patients with severe asthma.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for inflammatory diseases, cancer, and autoimmune disorders. Established in 2007 and headquartered in Atlanta, Georgia, the company is engaged in developing drug compounds that manipulate immune cell migration and activation. One of its key products, CTX-4430, is a small-molecule drug designed to inhibit the enzyme Leukotriene A4 hydrolase in immune cells, targeting conditions such as cystic fibrosis and moderately severe acne. Celtaxsys aims to provide innovative treatments that address the protective mechanisms of certain tumors, thereby enhancing the immune response against cancer and managing serious inflammatory conditions.

Centizyme develops a nanoparticle-based treatment for severe asthma. The therapy, called GeneRegs, is made from gold nanoparticles, coated with an enzyme that directly targets a protein that causes asthma symptoms. Because the gold nanoparticles are so small, they can be safely inhaled, delivering targeted therapy directly to the lungs – unlike oral steroids, which attack that same protein throughout the entire body. The systemic approach of steroids suppresses the immune system and causes other negative side effects, including osteoporosis and diabetes. The targeted approach of GeneRegs makes it a promising therapy that could provide a better and safer alternative to oral steroids and improve outcomes for approximately 1.5 million patients with severe asthma.

Covanos is a development-stage medical technology company focused on diagnosing and treating cardiac and vascular diseases. The company specializes in creating advanced digital medical diagnostic software solutions that leverage sophisticated mathematical methods and computational fluid dynamics. Their software evaluates coronary obstructions by analyzing CT angiography images of the heart, providing critical clinical information to physicians in near real-time. This enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance medical diagnostics in the cardiovascular field, ultimately improving patient outcomes.

Abby Med operates a pharmaceutical company that specializes in developing drugs for treating cancer.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Reservoir is a Greek company founded in 2016 that specializes in wireless irrigation solutions for landscapers and horticulturists. Its flagship product, Reservoir Spoke, allows users to manage irrigation systems remotely via smartphones or computers from any location. This innovative technology simplifies the installation and maintenance of irrigation systems by eliminating the need for traditional hardware components such as wires, controllers, and surge arresters. With Reservoir Spoke, landscapers can easily add new valves without the complexities of wiring, while growers benefit from automated irrigation with reduced risk of lightning damage.

MicroBplex is a biotechnology company focused on creating a diagnostic platform for the identification of microbial infections, specifically pneumonia and influenza. The company utilizes a novel technology that detects newly synthesized antibodies secreted by specialized Antibody Secreting Cells (ASCs) present in a patient's bloodstream during acute infections. By enabling early detection and assessment of therapeutic effectiveness, MicroBplex aims to help healthcare professionals differentiate new infections from previous ones, which is crucial for effective early therapeutic intervention. This innovative approach seeks to enhance diagnostic capabilities and improve patient outcomes in the management of infectious diseases.

TendoNova is a medical technology company focused on developing systems for office-based orthopedic procedures that address tendon injuries and pain. The company specializes in creating micro-invasive devices that facilitate percutaneous tenotomy, which can be performed under ultrasound guidance. This approach allows physicians to deliver tailored treatment options that meet the specific needs of individual patients while minimizing additional costs. By providing customizable modalities, TendoNova enhances the capabilities of clinicians, promoting effective and efficient orthopedic care in an office setting.

RePredix develops an acuity algorithm to predict and warn patients of potential heart failure. Its initial algorithm proved that heart failure can be diagnosed using wristband data.

NanoV Therapeutics develops a novel-mechanism anti-cancer drug. The compound, known as VPOA-6, has demonstrated high effectiveness in inhibiting tumor growth and combating a wide variety of cancers, with much less cytotoxicity than other leading drugs (Cisplatin, one of the most common first-line anti-cancer treatments). NanoV intends to use their newly discovered mechanism, utilizing redox catalysis, to develop a new class of anti-cancer agents to bring life-saving treatment to cancer patients. With drug resistance becoming a more pronounced obstacle to cancer treatment, novel mechanisms that demonstrate efficacy and safety have the potential to earn a large market. VPOA-6 significantly suppresses a wide range of cancers, including multi-drug resistant types. The synthesis and purification of VPOA-6 are readily accomplished in eco-friendly circumstances, requiring no toxic waste, and costing significantly less than existing cancer drugs.

Covanos is a development-stage medical technology company focused on diagnosing and treating cardiac and vascular diseases. The company specializes in creating advanced digital medical diagnostic software solutions that leverage sophisticated mathematical methods and computational fluid dynamics. Their software evaluates coronary obstructions by analyzing CT angiography images of the heart, providing critical clinical information to physicians in near real-time. This enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance medical diagnostics in the cardiovascular field, ultimately improving patient outcomes.

BioPace develops a hardware-free “biological pacemaker” to complement or replace traditional implantable devices. The technology uses mRNA-mediated gene transfer – called Tbx18 transduction – to deliver a human gene that dictates the formation of pacemaker tissue. When TBX18 is re-expressed within an adult human, the hallmark features of native pacemaker tissue in the heart are reproduced. When combined with a small molecule, A83-01, TBX18-induced pacemaker cells have proven durable. BioPace’s published data demonstrates the feasibility of the concept in small and large animal models. As of spring 2021, the company was working to further validate the concept for clinical application.

Sanguina is a medical device and wellness tool company that specializes in point-of-care diagnostics, particularly for hemoglobin determination. The company is focused on launching its first product, AnemoCheck Mobile, which is a non-invasive smartphone application designed for tracking hemoglobin levels without the need for painful blood draws. This innovative approach emphasizes anemia screening through color-based testing, allowing users to conveniently monitor their hemoglobin levels.

Nutrivert is a biotechnology company focused on developing postbiotics as an alternative to antibiotics for livestock. Its innovative formulation serves as a feed additive that enhances feed conversion efficiency, helping farmers achieve better productivity from their animals. Additionally, Nutrivert's postbiotics selectively target and eliminate bacteria that are susceptible to traditional antibiotics, allowing for improved livestock health and effective management of bacterial diseases. This approach not only supports sustainable farming practices but also addresses the growing concerns related to antibiotic use in agriculture.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

Diasyst specializes in developing innovative solutions for chronic disease management, focusing primarily on diabetes. The company offers a Medication Intelligence platform that empowers healthcare providers to make informed treatment decisions efficiently. By gathering and analyzing critical real-time data through proprietary algorithms, Diasyst provides tailored medication intervention recommendations, enhancing the ability of care teams to deliver safe and effective treatment. Their extensive knowledge base, built from decades of research at Emory University and the VA, encompasses clinical guidelines, drug labels, and best practices. This approach not only aims to improve patient care and engagement but also seeks to optimize clinical and financial outcomes by reducing the risks of complications associated with chronic conditions.

Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.

Urjanet, Inc. is a company that offers a cloud-based platform designed to streamline access to utility data. By connecting directly to utility providers, Urjanet acquires and normalizes utility bills and interval data, enabling organizations to automate data collection and enhance decision-making processes. Its offerings include a range of data-as-a-service solutions, such as automated access to utility bill data, granular measurements of energy consumption, and advanced metering infrastructure data. The platform also provides tools for users to submit utility credentials securely, as well as alerts for billing and consumption irregularities. Urjanet's data services support business intelligence, energy management, accounting, and procurement, helping organizations improve financial performance, energy efficiency, and sustainability. Founded in 2009 and headquartered in Atlanta, Georgia, with an additional office in Chennai, India, Urjanet aims to transform how organizations utilize utility data across various industries.

Sophia Bioscience develops new pharmaceutical treatments for early and metastatic cancers. It aims to increase the effectiveness of established drugs while lowering their required dosage and minimizing side effects. Sophia Bioscience also works to improve the drug development process, shortening the time to develop and significantly lowering associated costs. The company is currently focused on treating prostate cancer. The first drug candidate Sophia has put forward uses an independent anti-tumor chemotype, HDACi, and exploits prostate tumor androgen receptors (AR) for a more selective delivery than existing drugs. By exploiting these receptors, the drug resolves the issue of insufficient accumulation in the tumor and localizes the effects of the HDACi.

Covanos is a development-stage medical technology company focused on diagnosing and treating cardiac and vascular diseases. The company specializes in creating advanced digital medical diagnostic software solutions that leverage sophisticated mathematical methods and computational fluid dynamics. Their software evaluates coronary obstructions by analyzing CT angiography images of the heart, providing critical clinical information to physicians in near real-time. This enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance medical diagnostics in the cardiovascular field, ultimately improving patient outcomes.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Neurotrack Technologies, Inc., established in 2012 and headquartered in Redwood City, California, specializes in digital health solutions for early detection and ongoing monitoring of cognitive impairment, particularly Alzheimer's and other dementias. The company offers a computer-based cognitive test, validated clinically and guided by patients, which can be administered in clinics or at home, fitting various workflows. Neurotrack's proprietary technology has been recognized with 11 patents and is registered as an FDA Class II medical device. The company has published 27 peer-reviewed papers, demonstrating its commitment to scientific rigor and innovation in transforming dementia diagnosis and management.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.

CellectCell is a development-stage company dedicated to providing novel cell isolation tools for life science research

RePredix develops an acuity algorithm to predict and warn patients of potential heart failure. Its initial algorithm proved that heart failure can be diagnosed using wristband data.

MoQuality Inc., founded in 2014 and headquartered in Atlanta, Georgia, specializes in artificial intelligence-driven mobile testing solutions. The company aims to enhance app quality and improve user experiences by providing tools that simplify and accelerate the testing process. MoQuality's flagship product, Barista, offers a scriptless test-automation experience, leveraging AI to generate user-centric test scenarios that automate testing across various mobile platforms and real devices. This platform allows developers to identify and address issues before releasing their applications, ensuring high-quality performance for both Android and iOS apps. MoQuality is supported by investors including Amity Ventures, Cox Enterprises, and Techstars.

MicroBplex is a biotechnology company focused on creating a diagnostic platform for the identification of microbial infections, specifically pneumonia and influenza. The company utilizes a novel technology that detects newly synthesized antibodies secreted by specialized Antibody Secreting Cells (ASCs) present in a patient's bloodstream during acute infections. By enabling early detection and assessment of therapeutic effectiveness, MicroBplex aims to help healthcare professionals differentiate new infections from previous ones, which is crucial for effective early therapeutic intervention. This innovative approach seeks to enhance diagnostic capabilities and improve patient outcomes in the management of infectious diseases.

Diasyst specializes in developing innovative solutions for chronic disease management, focusing primarily on diabetes. The company offers a Medication Intelligence platform that empowers healthcare providers to make informed treatment decisions efficiently. By gathering and analyzing critical real-time data through proprietary algorithms, Diasyst provides tailored medication intervention recommendations, enhancing the ability of care teams to deliver safe and effective treatment. Their extensive knowledge base, built from decades of research at Emory University and the VA, encompasses clinical guidelines, drug labels, and best practices. This approach not only aims to improve patient care and engagement but also seeks to optimize clinical and financial outcomes by reducing the risks of complications associated with chronic conditions.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.

NovAb operates as a biotechnology company. The company commercializes monoclonal antibody technology. This organization primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, Accounting, Research, and Management Services sector.

Diasyst specializes in developing innovative solutions for chronic disease management, focusing primarily on diabetes. The company offers a Medication Intelligence platform that empowers healthcare providers to make informed treatment decisions efficiently. By gathering and analyzing critical real-time data through proprietary algorithms, Diasyst provides tailored medication intervention recommendations, enhancing the ability of care teams to deliver safe and effective treatment. Their extensive knowledge base, built from decades of research at Emory University and the VA, encompasses clinical guidelines, drug labels, and best practices. This approach not only aims to improve patient care and engagement but also seeks to optimize clinical and financial outcomes by reducing the risks of complications associated with chronic conditions.

Sanguina is a medical device and wellness tool company that specializes in point-of-care diagnostics, particularly for hemoglobin determination. The company is focused on launching its first product, AnemoCheck Mobile, which is a non-invasive smartphone application designed for tracking hemoglobin levels without the need for painful blood draws. This innovative approach emphasizes anemia screening through color-based testing, allowing users to conveniently monitor their hemoglobin levels.

Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.

Codoxo, previously known as Fraudscope, specializes in developing an AI-assisted platform aimed at enhancing the efficiency and affordability of healthcare systems. The company employs a patented algorithm to detect fraud, waste, and abuse within healthcare plans, enabling earlier identification of suspicious activities compared to traditional methods. This innovative approach supports investigators and analysts in deriving insights and conducting comprehensive investigations of questionable claims. By focusing on these critical areas, Codoxo helps ensure that healthcare resources are allocated effectively, ultimately contributing to improved patient care.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

Covanos is a development-stage medical technology company focused on diagnosing and treating cardiac and vascular diseases. The company specializes in creating advanced digital medical diagnostic software solutions that leverage sophisticated mathematical methods and computational fluid dynamics. Their software evaluates coronary obstructions by analyzing CT angiography images of the heart, providing critical clinical information to physicians in near real-time. This enables healthcare professionals to make informed decisions regarding revascularization and assess the risk of future coronary events, such as heart attacks. Covanos aims to enhance medical diagnostics in the cardiovascular field, ultimately improving patient outcomes.

Accuitis, Inc. is a pre-clinical-stage biopharmaceutical company founded in 2011 and based in Alpharetta, Georgia. The company specializes in the acquisition, development, and marketing of pharmaceuticals aimed at niche, orphan, and underserved disease states. Accuitis focuses on creating drug therapies for conditions such as rosacea, as well as other topical skin and eye diseases. Its product offerings include a proteasome inhibitor for rosacea treatment, alongside therapeutics targeting skin aging, acne, and dry eye conditions. Through its targeted approach, Accuitis aims to address significant unmet medical needs in these areas.

TendoNova is a medical technology company focused on developing systems for office-based orthopedic procedures that address tendon injuries and pain. The company specializes in creating micro-invasive devices that facilitate percutaneous tenotomy, which can be performed under ultrasound guidance. This approach allows physicians to deliver tailored treatment options that meet the specific needs of individual patients while minimizing additional costs. By providing customizable modalities, TendoNova enhances the capabilities of clinicians, promoting effective and efficient orthopedic care in an office setting.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

CellectCell is a development-stage company dedicated to providing novel cell isolation tools for life science research

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

CorAmi is an early stage therapeutics company developing a combination platform drug delivery device and therapeutic hydrogels.

MetCure Therapeutics is a biotechnology company that develops new drugs to treat metastatic cancer. It has developed a prostate cancer cell line that exhibits the characteristics of malignant, chemo-resistant human cancer cells. Using its proprietary high-throughput screening platform, MetCure is testing and identifying compounds that serve as effective drugs against these lethal cells. MetCure has identified LG1980 as one lead compound and outlined the mechanism LG1980 uses to attack prostate cancer cells. Other cancer stem cell inhibitors are also being explored.

LymphaTech is a healthcare technology company based in Atlanta, Georgia, focused on treating and preventing lymphedema. Founded in 2014, the company offers a 3D body scanning solution that measures leg circumference to create detailed three-dimensional models of limbs. This technology enables healthcare providers to diagnose lymphedema more effectively and monitor changes in limb volume over time. The 3D scans can be conducted in various settings, including at home or in a doctor's office, facilitating early detection of symptoms and timely intervention. By improving diagnosis and treatment options, LymphaTech's innovative approach aims to enhance the quality of life for patients, particularly breast cancer survivors, while providing valuable tools for clinicians and physical therapists.

CloudTags is a developer of a digital platform designed to enhance the shopping experience in physical retail stores. The platform provides retailers with insights into customer behavior, specifically identifying products that customers consider but do not purchase. Additionally, it captures email information for customers who are not ready to buy, allowing retailers to engage with these customers effectively. By leveraging this data, CloudTags enables retailers to better understand their customers' preferences and optimize their outreach strategies.

NovAb operates as a biotechnology company. The company commercializes monoclonal antibody technology. This organization primarily operates in the Biotechnical Research, Commercial business / industry within the Engineering, Accounting, Research, and Management Services sector.

Abby Med operates a pharmaceutical company that specializes in developing drugs for treating cancer.

AlphaStem is a healthcare device manufacturer located in Mineral Wells, Texas. The company focuses on the design and production of cranial electrotherapy simulator devices, which are intended to treat conditions such as anxiety, insomnia, depression, and pain. These devices are tailored for use in medical facilities, physician offices, and in home settings, providing patients with accessible treatment options for their mental health and pain management needs. AlphaStem operates within the biotechnical research sector, emphasizing its commitment to innovation in healthcare technology.

RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of virus-related death for infants, particularly premature infants. Elderly people are also at risk from RSV.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology aimed at treating mitral regurgitation. The company's device is designed to address the leaflets of heart valves while preserving the natural geometry of the mitral valve. By utilizing a proprietary implant, Nyra Medical's technology enables patients to achieve consistent correction of valve regurgitation, improving their overall heart function.